Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa

DALLAS, Oct. 31, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a BLA filing-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that positive 2-year results from the Phase 2b RESTORE randomized, controlled clinical trial (RCT) of...